The effect of altering the strain of the test virus used in the standardized pseudorabies virus neutralization (VN) test on the sensitivity of the assay was evaluated. Comparative VN tests were performed using 4 different strains: the avirulent Bartha parental, the avirulent recombinant Bartha gIII Ka , the moderately virulent Shope (currently used for the VN test at the National Veterinary Services Laboratory, Ames, IA), and the highly virulent P2208 (Funkhauser). A radioimmunoassay and a Western immunoblotting technique were employed to verify the presence of anti-pseudorabies virus (PrV) antibodies in sera. Statistical analysis indicated that replacement of the Shope strain by the Bartha gIII Ka or the P2208 strain resulted in VN titers that were 4.23-and 2.00-fold higher, respectively. Despite these differences, specificity with regard to PrV diagnosis was unaltered. This apparent enhancement of the sensitivity of the PrV VN test would be beneficial for the serologic identification of PrV-infected animals during an eradication effort.
Laboratory, USDA, APHIS, Ames, IA). A review of diagnostic laboratory experience with the various ELISA systems developed since 1986 and a latex bead agglutination test for such diagnostic use is given by Kinker. 13 Because these systems tend to detect all types of antiviral antibodies, not just virus-neutralizing antibodies, their ability to detect a humoral immune response (sensitivity) is an improvement over the standard VN test. In addition, most tests are not troubled by toxicity of a sample. However, even though such serologic assays are more sensitive than the standard PrV VN test, they may not quantify the host's ability to neutralize a field virus infection as simply as does a VN test. Furthermore, verification of ELISA-positive results seems to require endpoint titration of the samples by the VN assay.
The purpose of this study was to determine whether the sensitivity of a standard PrV VN assay could be improved by employing a different PrV test strain. However, because increased sensitivity must not be accompanied by decreased specificity, VN test specificity was also examined.
Materials and methods
Virus strains. All PrV strains were propagated in a Crandell-Rees feline kidney (CRFK) cell line using Eagle minimal essential media (MEM) a supplemented with 2% calf serum b and penicillin c (100 U/ml), streptomycin c (100 µg/ml), and gentamicin c (0.25 mg/ml). The Shope, d P2208, d and 2 Bartha strains (parental and gIII Ka ) e were used. Bartha parental is an avirulent strain used for European vaccine production. Bartha gIII Ka is a genetically engineered recombinant of the Bartha parental strain in which the original gIII has been replaced with the gIII coding sequence of the Kaplan (Ka) strain. 14, 23 For the Western immunoblotting assay, PrV-Shope was purified in a 30-60% discontinuous neutral sucrose gradient that was centrifuged for 4 hr at 112,700 x g and 4 C. Virus in the 40-50% interface was further purified by centrifugation in a 30-60% continuous neutral sucrose gradient for 18 hr at 112,700 x g and 4 C.
Serum samples. Porcine sera from field cases were obtained after testing from the Illinois Bureau of Animal Disease Laboratory at Galesburg. f The diagnostic VN tests done at the Galesburg Laboratory produced low VN titers for these field sera, using the Shope strain as the test virus. Serum samples from non-PrV-infected pigs were used as negative control sera for a radioimmunoassay (RIA). In addition, a group of 9 sera that were RIA positive but were negative based on the diagnostic VN test (Galesburg Laboratory) were evaluated in the experimental VN assay using the Bartha gIII Ka strain as the test virus.
Virus neutralization assay. A slight modification of the standardized PrV VN procedure 9 was followed for the experimental (Bartha parental, Bartha gIII Ka , P2208, and Shope) VN assays done in our laboratory. The modification involved the use of CRFK cells as the indicator cell line. All samples were tested undiluted (final dilution of 1:2) to a 1:64 final dilution and in quadruplicate. The virus strains were diluted so that 25 µ1 of each contained 100-300 TCID 50 (50% tissue culture infective dose). All diagnostic (Shope) VN tests referred to were done at the Galesburg Laboratory and followed the standardized procedure 9 by using pig kidney (PK-15) cells for virus detection. In experiment 1, each serum sample was tested against 3 PrV strains (Bartha gIII Ka , Shope, and P2208) on each of 2 consecutive days. The experimental VN test consisted of 8 serum samples selected from each of the diagnostic (Shope) VN titer levels (2, 4, and 8) . Twenty-four samples with a negative diagnostic titer (< 2) were also tested. Experiment 2 was conducted in a similar manner for comparison of the Bartha strains (parental and gIII Ka ) with the Shope strain, using a total of 24 samples: 6 sera from each diagnostic titer level (<2, 2, 4, and 8). The additional group of 9 sera, which were identified as negative for a diagnostic VN titer (<2) yet were positive for anti-PrV antibodies by RIA, were tested against the Bartha gIII Ka strain. All antibody titers were recorded as the reciprocal of the logarithm (to base 2) of the highest serum dilution that showed viral cytopathic effect (CPE) inhibition in 3 out of the 4 wells. Titer results from both experiments for each serum sample were compared for day-to-day test consistency and were averaged for the virus strain comparisons.
Radioimmunoassay. The single-dilution indirect solidphase RIA 27 was used to verify the VN test results obtained in experiment 1. The positive cutoff value utilized was 3.0 SD above the mean net counts produced by the sera from 24 age-matched non-PrV-infected pigs (negative control sera). For the additional group of diagnostic VN negative, sera (9 samples), sera from 40 age-matched normal pigs were used as the negative controls for the RIA, Western immunoblotting assay. Purified viral (PrV-Shope) and uninfected CRFK cellular preparations (cellular lysate prepared in same manner as for viral proteins) were subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electro-phoresis using a 10-17.5% resolving gel prepared as described. 7 One-half of the gel consisted of the viral antigens and the other half of the cellular preparation. The separated viral and CRFK cellular polypeptides were electroblotted to a nitrocellulose sheet g for 2 hr at 4 C using a Semiphor h semidry transfer unit with transfer buffer (200 mM Trizma base, 150 mM glycine [pH 8.01 20% [v/v] methanol). After transfer, the membrane was incubated with a blocking buffer (phosphate-buffered saline [PBS] 10-mM Tris-HC1 [pH 7.51, 0.1% Tween-20) with 15% normal goat serum (NGS) for 1 hr at 25 C on a rocker platform. The intact nitrocellulose sheet was then mounted in an apparatus (Miniblotter System') that forms multiple, separate individual channels over the membrane. The serum samples were each diluted 1:25 and were incubated with viral and cellular polypeptides (contained in the individual apparatus channels) for 1 hr at 25 C on a rocker platform. Porcine high VN-titered anti-PrV serum and mouse monoclonal anti-PrV gIII ascitic fluids (M 16) 8 served as positive controls. The channels were washed with 400 ml of washing buffer (PBS, 10 mM Tris-HC1 [pH 7.51, 0.1% Tween-20) prior to incubation with biotinylated affinity-purified goat anti-porcine IgG (H and L chains) antibodiesi diluted 1:250 in blocking buffer with 5% NGS for 1 hr at room temperature on a rocker platform. The channels were washed as before followed by the addition of an avidin DH biotinylated alkaline phosphatase H complex detection systemj reagent according to manufacturer instructions and incubation at 37 C for 30 min. After washing as above, the membrane was removed from the apparatus and incubated with a substrate solution composed of a 1:100 dilution of 5-bromo-4-chloro-3-indolyl phosphate c stock solution (2 mg in 100 µ1 DMSO) with nitroblue tetrazolium c (0.2 mg/ml of 100 mM Tris-HC1 [pH 9.71, 5 mM MgCL 2 , 10 µM ZnC1 2 ). The substrate was allowed to react with the membrane-bound alkaline phosphatase for several minutes at 37 C. The chromogenic reaction was stopped by placing the membrane in distilled water.
Statistical Analysis. Examination of the distributional
properties of the experimental VN titer estimates, by level of the diagnostic VN titer (with titers expressed as the reciprocal of dilution), indicated increasing variance with higher diagnostic titer. This heterogeneity of variance was corrected by a logarithmic transformation (to base 2) of all titer values, thus satisfying the homogeneity of variance requirement for regression models. All statistical analyses were conducted using these transformed scores. The reliability of experimental titer determinations was assessed by comparing measurements on 2 subsamples (VN tests conducted on 2 separate days) for each serum sample. A l-way analysis of variance was used to estimate reliability? The reliability estimations were performed separately for the Shope, the P2208, and the Bartha gIII Ka strains used in experiment 1. The effect of the PrV strain on the experimental VN test results were analyzed using a repeated measures regression model for a split plot design. 3 The dependent variable was the mean of the 2 titer levels for a serum sample. The diagnostic VN titer estimate was a covariate in the between-samples analysis. The test strains and the diagnostic titer by test strain product were the main effect and interaction effect factors in the within-samples analysis of variance. The test strain was coded as 2 dummy variables 3 with Shope as the comparison strain. With 24 samples, experiment 1 had high statistical power (>0.80) to detect even a small contribution to variance in VN titer (e.g., 5% out of total R 2 = 0.75) for each test strain. In experiment 2, with 18 samples, there is a slightly lower power of 0.69 under the same conditions. Thus, the experimental design has sufficient power to detect even small effects in virus strain differences and provides confidence that nonsignificant results truly indicate no effect of virus strain on VN titers.
Results

Virus neutralization.
The potential influence of the strain of PrV on the VN test was evaluated using sera previously determined to have low diagnostic VN titers (Galesburg Laboratory). In the first experiment, 24 VN-positive (titers of 2, 4, and 8) and 24 VN-negative (titer <2) sera were used independently on 2 different days in experimental VN assays against 3 PrV strains (Bartha gIII Ka , Shope, and P2208). In the second experiment, 24 serum samples (6 sera from each diagnostic VN titer level of <2, 2, 4, and 8) were tested in a similar manner to compare experimental VN titers obtained with Bartha parental, Bartha gIII ka , and Shape strains.
The reliability analysis for the experimental VN test results in experiment 1 was assessed comparing subsamples of each serum tested on 2 different days. This analysis yielded estimated reliabilities of 0.90 for the Shope strain, 0.86 for the Bartha gIII Ka strain, and 0.82 for the P2208 strain. Using 1 -way analysis of variance, 5 the estimated reliabilities of the subsample means was 0.94 for the Shope strain, 0.92 for the Bartha gIII Ka strain, and 0.90 for the P2208 strain, meeting the most stringent requirements specified for measurement reliability. 17 Between-day comparisons of mean titer for experimental results indicated a ratio of 1.00 for Shope, 1.09 for P2208, and 1.12 for Bartha gIII Ka The standardized PrV VN test method used in this study had both high between-day correlation (reliability) and stability (minimal day-to-day bias). Hence, titer differences between the various strains are not due to measurement error but are reflections of the sensitivity of each strain to neutralization.
In both experiments, the diagnostic (Shope) VN titer (done at the Galesburg Laboratory) was highly correlated with the experimental VN titer (done in our laboratory) using the Shope strain (Pearson's r for log,transformed titers: experiment 1 = 0.93, experiment 2 = 0.88). Specifically, the repeated measures regression analysis indicated a positive correlation of the diagnostic titer with the experimental Shope titer (Figs.  1, 2) . However, the diagnostic laboratory VN titers were consistently somewhat higher (1.48-fold higher in experiment 1 and 1.98-fold higher in experiment 2). In comparison of the 3 PrV strains, a significant effect (P < 0.01) of the virus strain used on the VN test result was observed. In experiment 1, virus test strain accounted for 29.3% of the variance in the experimental VN titers. The results of the regression analysis for experiment 1 are displayed in Figure 1 . When com- Figure 2 . The Bartha gIII Ka and Bartha parental strain, in comparison to the Shope strain, produced titers that were 6.03-and 1.67-fold higher, respectively. In both experiments the effect of test strain was independent of the diagnostic titer (i.e., no significant interaction effect).
Radioimmunoassay
The specificity of the VN results for the Bartha gIII Ka , P2208, and Shope strains (experiment 1) were verified by a single-dilution indirect solid-phase RIA technique. The 24 negative serum samples that were applied as negative controls for experiment 1 gave <O mean net counts (Table 1) . These sera were negative by the diagnostic (Shope) VN test (titer <2). The sera with diagnostic VN titers of 2, 4, and 8 produced RIA mean net counts that were positive for anti-PrV IgG antibodies (3.0 SD above the mean of the negative controls). In addition, the RIA count levels increased with respect to the increasing VN titers. The ranges of counts for each titer are clearly distinct. Good agreement between the two assays is found with humoral immune responses to chronic PrV infections when IgG predominates and many viral antigens are recognized, not just the neutralizing epitopes. 27 Therefore, chronicity of infection is most likely the reason for the correlation seen in Table 1 between the two assays.
Conflicting results were obtained with 9 sera tested by the VN test using the Shope strain and the RIA ( Tables 1, 2 ). Although the sera were established as negative by the diagnostic and the experimental Shope VN tests, they contained anti-PrV antibodies when assayed by RIA. These 9 sera also were positive by the experimental Bartha gIII Ka VN test (Table 2) , illustrating that the Bartha gIII Ka strain is more sensitive than the Shope strain and also retains specificity. Therefore, the Bartha gIII Ka strain provides a clear advantage when testing sera with low antibody titers. Moreover, the toxicity of a serum sample (animal 5) in the diagnostic (Shope) VN test was eliminated upon higher dilution in the experimental Bartha gIII Ka VN test, thus allowing detection of anti-PrV antibodies. The apparent lack of correlation between the Bartha gIII Ka VN titers and the RIA values ( Table 2) results from detection of different subsets of antibody molecules by the RIA. Such differences are most evident during an acute as opposed to a chronic PrV infection. 27
Western immunoblotting assay
All sera used in experiments 1 and 2 were evaluated by a Western immunoblotting assay to determine whether the VN results represented a humoral immune response to specific PrV polypeptides. This assay involved both viral and cellular purified polypeptides. All the VN-positive sera recognized the viral antigens gX, gIII, and gIV, which is significant because anti-gIII antibodies have been reported as important for successful neutralization of the virus 1 The other viral antigen that induces neutralizing antibodies is gp50. 4 Recognition of this viral glycoprotein was only de- tected for the high VN-titered control serum. Some serum samples also identified the viral antigens gIIa, gIIb, and gV. The negative control sera did not detect virus-specific polypeptides by this technique. Results of a representative assay are shown in Fig. 3 .
Discussion
There are several sources of variation for the VN test: the quality of the serum antibody (avidity and affinity), technical matters that result in between-day variation, the sensitivity of the cell line used as the detection system, and the virus strain used as the test virus. The extent of neutralization due to antibody quality can be improved somewhat by the addition of complement for subsequent viral inactivation. l6, 26 But in general,, insufficient antibody-virus neutralization interactions are not controlled easily in the diagnostic setting. There may be numerous factors responsible for between-day variation. The handling, storage, and initial condition of the test serum sample, as well as the technical skill level, contribute the most to such differences. However, we have shown that statistically significant between-day differences were not apparent in this study. Furthermore, our results indicate high agreement between laboratories. Our experimental Shope results showed only slight yet consistent deviations from the diagnostic VN titers (diagnostic titers were 1.48-fold higher in experiment 1 and 1.98-fold higher in experiment 2). In addition, the VN titer differences were not a result of cellular insensitivity to virus infection. The experimental VN test used the CRFK cell line and produced similar titer results with the Shope strain as did the diagnostic VN test, which used the PK-15 cell line. Therefore, the experimental titer variations appeared to be due to the differential sensitivity of the virus strains to neutralization by anti-PrV antibodies. Statistical analysis indicated that the VN titer was highly dependent on the test strain used (Figs. 1, 2) . The P2208 strain had VN titers that averaged twice as high as those for the Shope strain. The Bartha gIII Ka strain was the most sensitive, with VN titers 4-6-fold higher than those for the Shope strain. The results of the RIA and the Western immunoblot assay revealed that specificity was not lost with the increased sensitivity, that is, false positive results were not apparent with the more sensitive Bartha gIII Ka strain. Moreover, randomly selected field samples (n = 306) have also been titered. These sera had also been previously tested at the Galesburg Laboratory using the standardized (Shope) VN assay. As a group, the sera had a wide range of diagnostic VN titers (< 2 to >256). Subsequently, the sera were examined in our laboratory using the Bartha gIII Ka VN test. Results similar to those in this study were obtained (Bartha gIII Ka titer was 4.79-fold higher than the diagnostic titer; unpublished data).
The Bartha parental strain has a defect in the leader sequence of the gIII gene, resulting in reduced incorporation of gIII to the viral envelope. 20 In the recombinant Bartha gIII Ka strain, the original gIII gene has been replaced with its homologue from the Ka strain. 14, 23 The increased sensitivity of Bartha gIII Ka to the neu-, tralization activity of anti-PrV antibodies is most likely due to 1) the increased expression of gIII on the envelope of the virus, 2) the immunodominance of this glycoprotein in the humoral immune response to PrV, 1 and 3) the apparently unique sensitivity of gIII Ka glycoprotein to neutralizing antibodies (Zuckermann and Ben-Porat, unpublished observation). The expression of gIII Ka in the Bartha strain confers upon it this similar exquisite sensitivity to neutralization by anti-gIII antibodies as it does for the Ka strain. However, the dominant role of gIII in viral neutralization seems to be unique to the certain PrV strains, one of them being the Kaplan strain, which differ significantly from other strains in regard to this protein (T. Ben-Porat, personal communication). 4 Further comparison studies are necessary to determine if the neutralization role of gIII in the Bartha gIII Ka strain makes this strain the most sensitive of the known PrV strains.
Because the Bartha gIII Ka strain is comparatively more sensitive to neutralization, some toxic serum problems may be avoided. Higher dilutions of such sera would conceivably decrease the concentration of the toxic component(s). The use of the Bartha gIII Ka strain significantly enhances the sensitivity of the VN test without decreased specificity and, thus, will enable the detection of anti-PrV antibodies at a higher dilution of test sera (Tables 1, 2). Positive VN tests were obtained for 4 serum samples that were RIA positive yet toxic in the currently used standardized diagnostic pseudorabies VN test (unpublished data). This modified VN test will be of immense practical value for the diagnostic laboratory situation and will avoid the previous necessity of rebleeding animals.
The results of this study demonstrate that the currently employed standardized VN assay, which uses the Shope strain, lacks the sensitivity necessary for detecting all swine with low humoral titers of PrVspecific VN antibodies. This situation will hinder the eradication campaign against PrV. Failure to detect nonclinically PrV-infected swine could result in outbreaks of disease in presumably PrV-free herds from an apparently unknown source of infection. Use of the Bartha gIII Ka strain may increase the sensitivity (while retaining the specificity) of the VN test for the detection of PrV-infected swine.
